Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Visit

EBMT 2024 | The MAGIC algorithm probability to predict outcomes at the onset of GvHD

James Ferrara • 16 Apr 2024

EBMT 2024

General

James Ferrara, MD, DSc, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York City, NY, introduces a system for the risk stratification of graft-versus-host disease (GvHD), particularly in the gastrointestinal (GI) tract. The MAGIC algorithm probability (MAP) predicts overall mortality at 6 months and response to treatment at day 28 based on the MAGIC composite score, which considers clinical features as well as biomarkers at the onset of GvHD. This interview took place at the 50th Annual Meeting of the EBMT in Glasgow, Scotland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

I hold a patent for serum biomarkers of acute GVHD which is licensed and for which I receive royalties.

Reducing steroid usage in the treatment of lower-risk GvHD

James Ferrara • 16 Apr 2024

The MAGIC model: a day 14 endpoint for acute GvHD clinical trials

James Ferrara • 16 Apr 2024

ST2 and REG3α as predictive biomarkers for GvHD

James Ferrara • 24 Apr 2023

A novel clinical trial endpoint for acute GvHD

James Ferrara • 24 Apr 2023

Related Videos

Cardiac biomarkers for immune checkpoint inhibitor-related myocarditis in cancer patients

Arjun Ghosh • 25 Apr 2024

Rethinking healthcare to improve affordability, sustainability, and patient outcomes

Richard Sullivan • 29 Apr 2024

The importance of nutrition in hematology and cancer care

Shireen Kassam • 24 Apr 2024

A trial investigating enoxaparin vs placebo as thromboprophylaxis in hospitalized older patients

Gregoire Le Gal • 29 Apr 2024